Pathologic Evaluation of the Supraoptic and Paraventricular Nuclei in Dementia

David Diodati, Lee Cyn-Ang, Andrew Kertesz, Elizabeth Finger

ABSTRACT: Background: The neuropeptide oxytocin, produced in the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus, is now understood to function as a neurotransmitter critical for various aspects of social cognition and prosocial behaviour. While patients with Frontotemporal dementia (FTD) display prominent and progressive deficits in such social behaviours, the integrity of these nuclei in FTD is not known. Methods: We conducted a quantitative neuropathologic examination of the SON and PVN from patients with FTLD with TDP-43 proteinopathy, Alzheimer’s disease, Lewy body disease and controls to determine whether significant pathologic changes or neuronal loss may contribute to the striking behavioural symptoms of FTD. Results: Contrary to predictions, we found both nuclei to be free of significant pathologic change (TDP-43) in FTLD. In contrast, tau related pathology was found in the PVN in Alzheimer’s disease, and alpha-synuclein pathology in the SON in patients with Lewy body dementia. Conclusions: These results indicate that the SON and PVN are resistant to FTLD TDP-43 pathology. They also support prior suggestions that the SON is resistant to Alzheimer’s disease (AD) related pathology, and extend this to demonstrate SON susceptibility to alpha-synuclein pathology in patients with Lewy body dementia.

RÉSUMÉ: Évaluation anatomopathologique des noyaux supraoptiques et paraventriculaires dans la démence. Contexte : On sait maintenant que l’ocytocine, un neuropeptide produit dans les noyaux supraoptiques (NSO) et paraventriculaires (NPV) de l’hypothalamus, agit comme un neurotransmetteur dont la fonction est importante pour différents aspects de la cognition sociale et du comportement prosocial. Les patients qui présentent une démence fronto-temporale (DFT) ont des déficits importants et progressifs de ces comportements sociaux. Cependant l’intégrité de ces noyaux dans la DFT n’a pas été étudiée. Méthode : Nous avons effectué un examen neuropathologique quantitatif des NSO et NPV de patients atteints de démence lobaire frontotemporale (DLFT) ayant une protéinopathie TDP-43, une maladie d’Alzheimer, une démence à corps de Lewy ainsi que chez des sujets témoins afin de déterminer si des changements anatomopathologiques importants ou une perte neuronale pouvait contribuer aux symptômes comportementaux évidents de la DFT. Résultats : Contrairement à nos attentes, nous n’avons pas constaté la présence de changements anatomopathologiques significatifs (TDP-43) dans la DLFT. Par contre, nous avons observé la pathologie tau dans le NPV de patients atteints de la maladie d’Alzheimer et des agrégats d’alpha-syncléine dans les NSO des patients atteints de démence à corps de Lewy. Conclusions : Ces résultats indiquent que le NSO et le NPV sont résistants à la pathologie TDP-43 de la DLFT. Ils appuient également les suggestions faites antérieurement à l’effet que le NSO est résistant à la pathologie de la maladie d’Alzheimer et ils démontrent de plus la susceptibilité du NSO aux agrégats d’alpha-syncléine chez les patients atteints de démence à corps de Lewy.


Frontotemporal dementia (FTD) is a neurodegenerative disorder featuring striking changes in personality including emotional blunting, increased self-centered behaviour, and poor judgment. At the cognitive level, patients with frontotemporal dementia have deficits in emotional processing including loss of empathy, decreased emotion recognition, and deficits in theory of mind. Recent work in humans has demonstrated that the neuropeptide oxytocin may facilitate emotional and social cognition in each of these domains in healthy adults. Oxytocin is produced in the supraoptic (SON) and paraventricular (PVN) nuclei in the hypothalamus. Despite the important role of oxytocin in many aspects of social cognition impaired in patients with FTD, little empirical data concerning the integrity of these nuclei in patients with frontotemporal dementia has been reported.

Oxytocin produced in the hypothalamus and released via the pituitary into the systemic circulation has previously been most strongly associated with uterine contractions and milk ejection during lactation. Oxytocin producing neurons from the SON and PVN also project directly to brain regions involved in reward processing, including the amygdala, nucleus accumbens and medial prefrontal cortex. These regions are severely affected by the neuropathologic changes associated with frontotemporal lobar degeneration (FTLD). Thus, damage to oxytocin...
projection neurons and synapses in these regions may contribute to the social cognitive deficits in FTD.

In addition to its role in pregnancy, oxytocin is now recognized to be an important mediator of social cognition across species and gender, specifically increasing pro-social behaviours. In animal models administration of oxytocin increases maternal behaviours including grooming, nesting, and pair bond formation. In humans, administration of oxytocin to healthy adults increases trust and cooperative behaviours, emotional empathy, facial expression recognition, and theory of mind skills. In addition, oxytocin administration to autistic patients facilitates social information processing and decreases repetitive behaviours.

Despite the social impairment in FTD and the association between social cognition and oxytocin neuronal systems, little is known about whether FTD related pathology affects the two main nuclei producing oxytocin. Frontotemporal dementia pathology has been examined in other hypothalamic nuclei, including reduced neuron to astrocyte ratios in the suprachiasmatic nucleus and significant pathologic changes in the lateral tubular nucleus in Pick’s disease. One recent study of the hypothalamus and eating disorders in patients with FTD found reduced posterior hypothalamic volumes compared to controls in TDP-43 positive patients, but no changes in the number of vasopressin containing neurons in the PVN.

Given the deficits in prosocial behaviours, empathy and emotion recognition in FTD, and the mediation of these processes by oxytocin, we hypothesized that damage to oxytocin producing nuclei may contribute to the abnormal social behaviour characteristic of patients with FTD. The purpose of this project was to characterize neurodegenerative pathology of the supraoptic and paraventricular nuclei in patients with autopsy confirmed FTD in comparison to patients with Alzheimer’s disease (AD) and Lewy body dementia (LBD). If neuro-pathologic changes in oxytocin producing nuclei give rise to deficits in social cognition, then we predicted that patients with FTD would show more abnormal protein inclusions and/or decreased neuronal densities in the SON and/or PVN compared to patients with Alzheimer’s disease, LBD and neurologically healthy comparison individuals.

**METHODS**

The autopsy database at London Health Sciences Centre (LHSC) was searched for patients with a final autopsy diagnosis of LBD, AD, or FTLD (excluding corticobasal syndrome or progressive supranuclear palsy (PSP)), excluding cases with other significant associated neuropathological findings such as infections, trauma, neoplasms or stroke. Age-matched controls were also selected from cases without known neurological diseases and no significant neuropathological findings on autopsy. Only cases with availability of the hypothalamus (namely, SON and PVN) either in the paraffin blocks or formalin fixed wet tissue were included. In most cases, fresh samples were taken from the formalin-fixed wet brain tissue and then embedded in paraffin wax for the study. The paraffin tissue blocks were cut in 5 um sections and put on positively charged slides using standard microtome procedure and stained with hematoxylin-eosin (HE). These sections were examined for the presence of the SON and PVN by identifying their characteristic groups of large cell bodies and location. If the SON or the PVN were absent, these blocks were resubmitted for leveling, and stained with HE at levels 1, 5, 10, 15, and 20. Leveled slides

![Figure 1](https://www.cambridge.org/core/core)
were then re-examined, and if these nuclei were still absent or insufficient for quantification, these cases were excluded from the study. After reviewing cases on the basis of final autopsy diagnosis and availability of hypothalamic tissue, 35 cases were selected [eight FTLD with TDP-43 proteinopathy (including 2 with FTLD plus motor neuron disease), 11 Alzheimer’s disease, 5 Lewy body dementia, and 9 age-matched controls (see Table)].

The paraffin sections from cases with SON and/or the PVN were submitted for immunohistochemistry with primary antibodies to phosphorylated tau (AT8, ThermoScientific, 1:400) alpha-synuclein (Zymed, 1:50), ubiquitin (Dako, 1:200), and TDP-43 (ProtemTechGroup, 1:1000) utilizing the ImmPRESS Peroxidase Polymer Detection Kit from Vector Laboratories, Southfield, MI. The area of each nucleus (SON or PVN) was determined using an Olympus BX51 microscope linked to SPOT software and manually tracing the outline of the nucleus. The neuronal density per nucleus was determined by counting the number of neurons utilizing the same software within the area delineated and the density was represented as neurons (nuclei) per mm². The SON and PVN were examined for inclusions for each of the immunostains; an inclusion was counted at 60X magnification if it was clearly within the boundaries of the SON or PVN. The number of tau, alpha-synuclein, ubiquitin or TDP-43 inclusions was quantified and normalized by the individual area of each nucleus. For TDP-43, nuclear staining was used as an internal positive control.

Statistical analysis: One-way analysis of variance (ANOVAs) with diagnosis as the between subject factor were performed for each nucleus (SON and PVN) and immunostain (TDP-43, tau, alpha-synuclein, ubiquitin) using the SPSS program. Additional ANOVAs with diagnosis as the between subject factor were conducted on the number of neurons per nucleus for the SON and PVN. Significant main effects were followed up with post-hoc t-tests between each group, and independent samples t-tests were conducted between the dementia groups and controls.

### Table: Clinical data and measures of protein inclusions per mm² in the paraventricular and supraoptic hypothalamic nuclei

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Age at death</th>
<th>Gender</th>
<th>FTLD subtype</th>
<th>FTLD clinical subtype</th>
<th>Years</th>
<th>TDP-43</th>
<th>Tau</th>
<th>alpha-synuclein</th>
<th>ubiquitin</th>
<th>TDP-43</th>
<th>Tau</th>
<th>alpha-synuclein</th>
<th>ubiquitin</th>
</tr>
</thead>
</table>
| FTLD= frontotemporal lobar degeneration; TDP-43 = tar DNA-binding protein 43; bvFTD = behavioural variant FTD; FTD = Frontotemporal dementia; LBD = Lewy Body Dementia; AD = Alzheimer’s disease; CTRL= Control; n/a = not available

were then re-examined, and if these nuclei were still absent or insufficient for quantification, these cases were excluded from the study. After reviewing cases on the basis of final autopsy diagnosis and availability of hypothalamic tissue, 35 cases were selected [eight FTLD with TDP-43 proteinopathy (including 2 with FTLD plus motor neuron disease), 11 Alzheimer’s disease, 5 Lewy body dementia, and 9 age-matched controls (see Table)].

The paraffin sections from cases with SON and/or the PVN were submitted for immunohistochemistry with primary antibodies to phosphorylated tau (AT8, ThermoScientific, 1:400) alpha-synuclein (Zymed, 1:50), ubiquitin (Dako, 1:200), and TDP-43 (ProtemTechGroup, 1:1000) utilizing the ImmPRESS Peroxidase Polymer Detection Kit from Vector Laboratories, Southfield, MI. The area of each nucleus (SON or PVN) was determined using an Olympus BX51 microscope linked to SPOT software and manually tracing the outline of the nucleus. The neuronal density per nucleus was determined by counting the number of neurons utilizing the same software within the area delineated and the density was represented as neurons (nuclei) per mm². The SON and PVN were examined for inclusions for each of the immunostains; an inclusion was counted at 60X magnification if it was clearly within the boundaries of the SON or PVN. The number of tau, alpha-synuclein, ubiquitin or TDP-43 inclusions was quantified and normalized by the individual area of each nucleus. For TDP-43, nuclear staining was used as an internal positive control.

Statistical analysis: One-way analysis of variance (ANOVAs) with diagnosis as the between subject factor were performed for each nucleus (SON and PVN) and immunostain (TDP-43, tau, alpha-synuclein, ubiquitin) using the SPSS program. Additional ANOVAs with diagnosis as the between subject factor were conducted on the number of neurons per nucleus for the SON and PVN. Significant main effects were followed up with post-hoc t-tests between each group, and independent samples t-tests were conducted between the dementia groups and controls.
RESULTS

Paraventricular Nucleus

The PVN was available for examination in eight patients with FTD TDP-43, ten patients with Alzheimer’s disease, five patients with Lewy body dementia and seven controls. In the PVN, the one-way ANOVAs demonstrated a significant main effect of diagnosis for the number of tau inclusions (F[3,29]=4.1, p<0.05) and for the number of alpha-synuclein inclusions (F[3,29]=3.1, p<0.05). For tau inclusions, post-hoc t-tests demonstrated significant differences between AD and controls (AD > controls) (t(15)=2.5; p<0.05), and AD and FTD groups (AD > FTD) (t(17)=2.4; p<0.05), while AD and LBD were not significantly different (Figure 1a). The tau immunohistochemistry demonstrated neurofibrillary tangles, mostly of the globose types and neuropil threads in the affected areas (Figure 2). Occasional round to oval intracytoplasmic inclusions were also observed in the neurons which do not resemble any classical neurofibrillary tangles.

Although post-hoc t-tests demonstrated a trend of greater alpha-synuclein inclusions in LBD vs. AD (t(13)=1.2, p<0.07) (Figure 3a), no significant differences in alpha-synuclein inclusions were found for LBD vs. controls or LBD vs FTD. There were no significant differences in neuron density (F[3,29]=0.19, p=ns) (Figure 1-B), or mean number of ubiquitin (F[3,29]=1.9, p=ns), or TDP-43 (F[3,29]=0, p=ns) inclusions in the dementia groups compared to controls (Table). Of interest, there were no TDP-43+ inclusions found in the PVN of any case.

Supraoptic Nucleus

The SON was available for examination in seven patients with FTD TDP-43, 11 patients with Alzheimer’s disease, four patients with Lewy body dementia and eight controls. The one-way ANOVAs demonstrated a significant main effect of diagnosis for alpha-synuclein inclusions (F(3,29) = 18.2, p<0.05) (Figure 2b). Follow up t-tests between LBD and the other groups demonstrated increased alpha-synuclein inclusions in LBD compared to patients with Alzheimer’s disease (t(13)=4.6, p<0.05), FTD TDP-43 (t(9)=4.4, p<0.05) and controls (t(10)=4.7, p<0.05) (Figure 3). In the affected areas, the alpha-synuclein immunohistochemistry demonstrated Lewy neurites, some of which appeared more globular, suggestive of...
intranuclear Lewy bodies, but no definite Lewy bodies of cortical or subcortical variants were identified (Figure 4). The remaining ANOVAs indicated that there were no significant differences or trends in the mean number of tau (Figure 1b), TDP-43, or ubiquitin inclusions or neuron density in the groups. There were no other trends of difference between AD and FTD groups and controls. Of interest, there were no TDP-43+ inclusions found in the SON of any case.

DISCUSSION

The present study evaluated the neuronal integrity and presence of neurodegenerative pathology in the two oxytocin producing nuclei of the hypothalamus across the three main neurodegenerative dementias. Counter to our predictions, in patients with FTD (TDP-43+) we did not find significant pathology in either nucleus. In contrast, patients with Alzheimer’s disease demonstrated significant tau pathology in the PVN, but not the SON, compared to controls and FTD patients. Increased alpha-synuclein inclusions were found in patients with Lewy body dementia compared to controls in the SON but not the PVN. Neuronal counts did not differ in either nucleus between the dementia groups and the controls. The present results demonstrate for the first time the integrity of these nuclei described above in the patients with Alzheimer’s disease. Further study of biochemical differences between the PVN and SON in Lewy body dementia and Alzheimer’s disease that may confer such resistance to specific neuronal inclusions could not only elucidate mechanisms for the selective vulnerability of other neurons in the CNS to these processes but also identify novel potential treatment targets for conferring neuronal resistance to alpha-synuclein or tau pathology.

The lack of significant FTD TDP-43 pathology in the SON and PVN indicates that neuronal damage and loss within these nuclei is not a contributing factor to the abnormal social and behavioral symptoms characteristic of the disorder, at least in this pathologic subtype. As our sample included only patients with the TDP-43 subtypes of FTD, conclusions about the involvement of the SON in other FTD subtypes such as FTD with tauopathy or fused in sarcoma (FUS) proteinopathy will require additional study. While the aim of the present study was to characterize the presence of neuropathology in the PVN and SON, the two oxytocin producing nuclei of the hypothalamus, other neurons in these nuclei produce vasopressin. In the PVN, approximately 50% of the neurons secrete oxytocin, while in the SON approximately 10–15% secrete oxytocin. Identification of oxytocin specific neurons in these nuclei was not possible due to the prolonged time in formalin for many of the samples, which precluded reliable staining for either the oxytocin peptide or receptor. Thus, it is possible that a selective reduction in oxytocin producing neurons may not be detected if other neuronal subtypes in the nuclei are preserved, particularly in the SON. Another consideration in the interpretation of our results is the finding of preserved neuronal counts despite the presence of increased Alzheimer disease pathology in PVN and LBD in the SON. However, this pattern is consistent with prior studies demonstrating similar dissociations between the presence of neurodegenerative pathology and neuronal cell loss in hypothalamic nuclei in Alzheimer’s disease and Parkinson’s disease. Thus, whether the inclusions found in the present
study in AD and LBD patients result in any significant impairment of the function of these nuclei cannot be presumed. Future studies evaluating additional protein markers of neuronal injury would further illuminate whether inclusions are associated with any signals of neuronal degeneration. In summary, we found that the two oxytocin producing nuclei of the hypothalamus, the SON and PVN, lack significant pathologic changes associated with FTLD with TDP-43 proteinopathy. In patients with AD and LBD, distinct patterns of disease related pathology in the PVN vs the SON raise intriguing questions for the relationship between specific inclusion types and selective vulnerability or resistance of these two hypothalamic neuronal populations. Future studies are required to assess whether damage to the SON and PVN in other subtypes of FTLD, or damage to oxytocinergic projections from the hypothalamic nuclei within the medial prefrontal cortex, amygdala and striatum may be implicated in the social deficits of FTD.

ACKNOWLEDGEMENTS

This research was supported by Summer Research Training Program, the Hazel Soper Foundation at the University of Western Ontario.

REFERENCES

43. Fliers E, Swaab DF, Pool CW, Verwer RW. The vasopressin and oxytocin neurons in the human supraoptic and paraventricular nucleus; changes with aging and in senile dementia. Brain Res. 1985 Sep 2;342(1):45-53.